Literature DB >> 14984200

Hepatitis C NS3 protease inhibition by peptidyl-alpha-ketoamide inhibitors: kinetic mechanism and structure.

Yaya Liu1, Vincent S Stoll, Paul L Richardson, Ayda Saldivar, Jeffrey L Klaus, Akhteruzzaman Molla, William Kohlbrenner, Warren M Kati.   

Abstract

A series of novel peptidyl-alpha-ketoamide compounds were evaluated as inhibitors of the deltaNS3-NS4A serine protease from the hepatitis C virus. These peptidyl-alpha-ketoamide inhibitors with Ki values ranging from 0.17 nM to 5.6 microM exhibited slow-binding inhibition. Kinetic studies established one-step kinetic mechanisms and dissociation rate constants in the 3-7 x 10(-5) s(-1) range for these compounds. The association rate constants, which ranged from 10 to 263,000 M(-1) s(-1), were responsible for the greater than four order of magnitude overall binding affinity range exhibited by this series. An X-ray crystal structure of a protease-inhibitor complex revealed an unusual interaction between the oxyanion of the adduct and the protein as well as a significant movement in the S1' region of the protein loop comprising residues 35-42. These results are quite different from peptidyl-alpha-ketoacid inhibition of HCV protease, which reportedly undergoes no notable conformational changes and proceeds with a two-step slow-binding kinetic mechanism.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14984200     DOI: 10.1016/j.abb.2003.11.013

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  7 in total

Review 1.  The drug-target residence time model: a 10-year retrospective.

Authors:  Robert A Copeland
Journal:  Nat Rev Drug Discov       Date:  2015-12-18       Impact factor: 84.694

2.  Can Relative Binding Free Energy Predict Selectivity of Reversible Covalent Inhibitors?

Authors:  Payal Chatterjee; Wesley M Botello-Smith; Han Zhang; Li Qian; Abdelaziz Alsamarah; David Kent; Jerome J Lacroix; Michel Baudry; Yun Luo
Journal:  J Am Chem Soc       Date:  2017-11-29       Impact factor: 15.419

3.  Novel Peptidomimetic Hepatitis C Virus NS3/4A Protease Inhibitors Spanning the P2-P1' Region.

Authors:  Anna K Lampa; Sara M Bergman; Sofia S Gustafsson; Hiba Alogheli; Eva B Akerblom; Gunnar G Lindeberg; Richard M Svensson; Per Artursson; U Helena Danielson; Anders Karlén; Anja Sandström
Journal:  ACS Med Chem Lett       Date:  2013-08-02       Impact factor: 4.345

Review 4.  Structure-kinetic relationships that control the residence time of drug-target complexes: insights from molecular structure and dynamics.

Authors:  Hao Lu; James N Iuliano; Peter J Tonge
Journal:  Curr Opin Chem Biol       Date:  2018-07-06       Impact factor: 8.822

5.  Rapid synthesis of internal peptidyl α-ketoamides by on resin oxidation for the construction of rhomboid protease inhibitors.

Authors:  Tim Van Kersavond; Raphael Konopatzki; Merel A T van der Plassche; Jian Yang; Steven H L Verhelst
Journal:  RSC Adv       Date:  2021-01-20       Impact factor: 3.361

6.  Identification of HCV protease inhibitor resistance mutations by selection pressure-based method.

Authors:  Ping Qiu; Vincent Sanfiorenzo; Stephanie Curry; Zhuyan Guo; Shaotang Liu; Angela Skelton; Ellen Xia; Constance Cullen; Robert Ralston; Jonathan Greene; Xiao Tong
Journal:  Nucleic Acids Res       Date:  2009-04-24       Impact factor: 16.971

7.  General and Modular Strategy for Designing Potent, Selective, and Pharmacologically Compliant Inhibitors of Rhomboid Proteases.

Authors:  Anežka Tichá; Stancho Stanchev; Kutti R Vinothkumar; David C Mikles; Petr Pachl; Jakub Began; Jan Škerle; Kateřina Švehlová; Minh T N Nguyen; Steven H L Verhelst; Darren C Johnson; Daniel A Bachovchin; Martin Lepšík; Pavel Majer; Kvido Strisovsky
Journal:  Cell Chem Biol       Date:  2017-10-26       Impact factor: 8.116

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.